These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Autotaxin in Pathophysiology and Pulmonary Fibrosis. Ninou I; Magkrioti C; Aidinis V Front Med (Lausanne); 2018; 5():180. PubMed ID: 29951481 [TBL] [Abstract][Full Text] [Related]
6. Plasma Concentrations of Lysophosphatidic Acid and Autotaxin in Abstinent Patients with Alcohol Use Disorder and Comorbid Liver Disease. Flores-López M; García-Marchena N; Pavon FJ; Lara E; Porras-Perales O; Araos P; Requena-Ocaña N; Torres-Galván S; Mañas-Padilla MC; Rubio G; Suárez J; Santín LJ; Rodríguez de Fonseca F; Castilla-Ortega E; García-Fernández MI; Serrano A Biomedicines; 2021 Sep; 9(9):. PubMed ID: 34572393 [TBL] [Abstract][Full Text] [Related]
7. The autotaxin-lysophosphatidic acid-lysophosphatidic acid receptor cascade: proposal of a novel potential therapeutic target for treating glioblastoma multiforme. Tabuchi S Lipids Health Dis; 2015 Jun; 14():56. PubMed ID: 26084470 [TBL] [Abstract][Full Text] [Related]
8. Roles of Autotaxin/Autotaxin-Lysophosphatidic Acid Axis in the Initiation and Progression of Liver Cancer. She S; Zhang Q; Shi J; Yang F; Dai K Front Oncol; 2022; 12():922945. PubMed ID: 35769713 [TBL] [Abstract][Full Text] [Related]
9. Exosome-associated lysophosphatidic acid signaling contributes to cancer pain. Khasabova IA; Khasabov SG; Johns M; Juliette J; Zheng A; Morgan H; Flippen A; Allen K; Golovko MY; Golovko SA; Zhang W; Marti J; Cain D; Seybold VS; Simone DA Pain; 2023 Dec; 164(12):2684-2695. PubMed ID: 37278638 [TBL] [Abstract][Full Text] [Related]
10. The autotaxin-lysophosphatidic acid pathway emerges as a therapeutic target to prevent liver cancer. Erstad DJ; Tager AM; Hoshida Y; Fuchs BC Mol Cell Oncol; 2017; 4(3):e1311827. PubMed ID: 28616586 [TBL] [Abstract][Full Text] [Related]
12. Production of extracellular lysophosphatidic acid in the regulation of adipocyte functions and liver fibrosis. Yang F; Chen GX World J Gastroenterol; 2018 Sep; 24(36):4132-4151. PubMed ID: 30271079 [TBL] [Abstract][Full Text] [Related]
15. Regulation of tumor cell - Microenvironment interaction by the autotaxin-lysophosphatidic acid receptor axis. Tigyi GJ; Yue J; Norman DD; Szabo E; Balogh A; Balazs L; Zhao G; Lee SC Adv Biol Regul; 2019 Jan; 71():183-193. PubMed ID: 30243984 [TBL] [Abstract][Full Text] [Related]
16. Dexamethasone decreases the autotaxin-lysophosphatidate-inflammatory axis in adipose tissue: implications for the metabolic syndrome and breast cancer. Meng G; Tang X; Yang Z; Zhao Y; Curtis JM; McMullen TPW; Brindley DN FASEB J; 2019 Feb; 33(2):1899-1910. PubMed ID: 30192654 [TBL] [Abstract][Full Text] [Related]
17. Characterization of the properties of a selective, orally bioavailable autotaxin inhibitor in preclinical models of advanced stages of liver fibrosis. Baader M; Bretschneider T; Broermann A; Rippmann JF; Stierstorfer B; Kuttruff CA; Mark M Br J Pharmacol; 2018 Feb; 175(4):693-707. PubMed ID: 29197066 [TBL] [Abstract][Full Text] [Related]
19. Single-cell transcriptome dynamics of the autotaxin-lysophosphatidic acid axis during muscle regeneration reveal proliferative effects in mesenchymal fibro-adipogenic progenitors. Contreras O; Harvey RP Front Cell Dev Biol; 2023; 11():1017660. PubMed ID: 36910157 [TBL] [Abstract][Full Text] [Related]
20. The linkage between inflammation and fibrosis in muscular dystrophies: The axis autotaxin-lysophosphatidic acid as a new therapeutic target? Gallardo FS; Córdova-Casanova A; Brandan E J Cell Commun Signal; 2021 Sep; 15(3):317-334. PubMed ID: 33689121 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]